AstraZeneca

AstraZeneca Liabilities

The The Liabilities of AstraZeneca (AZN.L) as of Nov 19, 2026 is 65.36 B USD. In the previous year, The Liabilities was 63.16 B USD — a change of 3.47% (higher).

Liabilities

65.36 BUSD

YoY

3.47%

Last updated:

In 2025, AstraZeneca's total liabilities amounted to 65.36 B USD, a 3.47% difference from the 63.16 B USD total liabilities in the previous year.

The AstraZeneca Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
46.61 B USD
Jan 1, 2019
46.78 B USD
Jan 1, 2020
51.09 B USD
Jan 1, 2021
66.08 B USD
Jan 1, 2022
59.43 B USD
Jan 1, 2023
61.95 B USD
Jan 1, 2024
63.16 B USD
Jan 1, 2025
65.36 B USD
The AstraZeneca Liabilities history
YEARLiabilitiesYoY
65.36 BUSD+3.47%
63.16 BUSD+1.95%
61.95 BUSD+4.25%
59.43 BUSD-10.07%
66.08 BUSD+29.33%
51.09 BUSD+9.21%
46.78 BUSD+0.37%
46.61 BUSD-0.22%
46.71 BUSD+1.86%
45.86 BUSD+10.19%
41.62 BUSD+6.84%
38.95 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing AstraZeneca's Liabilities

AstraZeneca's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AstraZeneca's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing AstraZeneca's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

AstraZeneca's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in AstraZeneca’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about AstraZeneca stock

The Liabilities of AstraZeneca is 65.36 B USD in 2025.

The Liabilities of AstraZeneca changed from 63.16 B USD to 65.36 B USD, representing a 3.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's AstraZeneca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AstraZeneca

All Key Metrics — AstraZeneca